These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12775732)

  • 1. Quality assessment of genetic markers used for therapy stratification.
    Ambros IM; Benard J; Boavida M; Bown N; Caron H; Combaret V; Couturier J; Darnfors C; Delattre O; Freeman-Edward J; Gambini C; Gross N; Hattinger CM; Luegmayr A; Lunec J; Martinsson T; Mazzocco K; Navarro S; Noguera R; O'Neill S; Potschger U; Rumpler S; Speleman F; Tonini GP; Valent A; Van Roy N; Amann G; De Bernardi B; Kogner P; Ladenstein R; Michon J; Pearson AD; Ambros PF
    J Clin Oncol; 2003 Jun; 21(11):2077-84. PubMed ID: 12775732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections.
    Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M
    Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.
    Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y
    Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
    Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
    Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
    Wan TS; Ma ES; Chan GC; Chan LC
    Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity.
    Ozer E; Altungoz O; Unlu M; Aygun N; Tumer S; Olgun N
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):181-6. PubMed ID: 17525631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children.
    Fröstad B; Martinsson T; Tani E; Falkmer U; Darnfors C; Skoog L; Kogner P
    Cancer; 1999 Apr; 87(2):60-8. PubMed ID: 10227595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
    Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
    Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral neuroblastic tumours in eastern Denmark 1972-2002.
    Zimling ZG; Rechnitzer C; Rasmussen M; Petersen BL
    APMIS; 2007 Jan; 115(1):66-74. PubMed ID: 17223852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA content heterogeneity in neuroblastoma analyzed by means of image cytometry and its potential significance.
    Melegh Z; Csernák E; Tóth E; Veleczki Z; Magyarosy E; Nagy K; Szentirmay Z
    Virchows Arch; 2005 May; 446(5):517-24. PubMed ID: 15827757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.